THE former finance director of ScottishPower has taken interim control at pharmaceuticals giant AstraZeneca.

Simon Lowth, 50, is stepping up to replace chief executive David Brennan, who abruptly announced his departure yesterday after six years in the job.

Mr Brennan's earlier-than-expected retirement sits alongside chairman Louis Schweitzer's move to leave three months ahead of schedule, to be replaced by ex-Volvo boss Leif Johansson.

Shareholders have been putting pressure on Mr Brennan, paid more than £9 million last year, after the group cut full-year profit forecasts following an 11% sales drop in the first quarter to $7.35 billion (£4.55bn). Pre-tax profits plunged by 38% from $3.3bn to $2.05bn in the first three months of 2012.

Longer-term prospects are also uncertain as multiple drug patents are expiring in the next few years with little in the pipeline to replace them.

Former McKinsey management consultant Mr Lowth is no stranger to boardroom shake-ups, having played a key part in an executive cull at ScottishPower in 2005, which saw him emerge as right-hand man to then-chief executive Ian Russell.

Mr Lowth joined AstraZeneca as chief financial officer in 2007 and will now take over as interim chief executive on June 1.

The company would not comment on individuals who may be in the running for the job full time but said a mixture of internal and external applicants would be considered.

Mr Lowth said the company was not rushing to change direction and he would be participating in the annual strategy review process with the rest of the board over the summer.

Outgoing chairman Mr Schweitzer said: "I know we can count on Simon's leadership, supported by a strong and experienced senior executive team, to maintain focus and momentum as the board seeks a smooth transition to a new chief executive over the coming months."

Mr Brennan also said he fully supported the decision to place Mr Lowth in charge.

The shares ended the day down 174.5 pence at £26.66.